---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-005310"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2025-02-07T23:59:59+00:00"
generated_at: "2026-05-27T01:18:07.032723+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aim ImmunoTech plans combo study of Ampligen and FluMist for avian flu

## Summary
- Plans to file IND for trial combining Ampligen with AstraZeneca's FluMist to target avian influenza.
- Prior UAB clinical data showed Ampligen + FluMist induced cross-reactive antibodies against H5N1, H7N9, H7N3.
- Pre-clinical work demonstrated 50-100% survival in mice challenged with H5N1 variants vs. 0-60% naive controls.
- AIM has engaged CRO Amarex for IND application and study management; seeking government/industry grants.

## SEC filing metadata
- accession: 0001493152-25-005310
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2025-02-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315225005310/0001493152-25-005310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315225005310/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-005310
- JSON: https://secwatch.observer/filing/0001493152-25-005310.json
- Plain text: https://secwatch.observer/filing/0001493152-25-005310.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.